Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids

Alimentary Pharmacology and Therapeutics

Volumn 41, Issue 1, 2015, Pages 116-125

  Robles Diaz, M ^a,b   Gonzalez Jimenez, A ^a   Medina Caliz, I ^a   Stephens, C ^a,b   Garcia Cortes M ^a,b   Garcia Munoz B ^a   Ortega Alonso, A ^a   Blanco Reina, E ^a   Gonzalez Grande, R ^c   Jimenez Perez, M ^c   Rendon P ^d   Navarro, J M ^e   Gines, P ^b,f   Prieto, M ^b,g   Garcia Eliz, M ^g   Bessone, F ^h   Brahm, J R ⁱ   Parana R ^j   Lucena, M I ^a,b   Andrade, R J ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^d HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^e HOSPITAL COSTA DEL SOL   (Spain)

^f HOSPITAL CLÍNIC   (Spain)

^g INSTITUTO DE INVESTIGACIÓN SANITARIA DEL HOSPITAL CLÍNICO SAN CARLOS IDISSC   (Spain)

^h UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

ⁱ PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^j FEDERAL UNIVERSITY OF BAHIA   (Brazil)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANDROGEN; BILIRUBIN; CREATININE; METHASTERONE; METHYLEPITIOSTANOL; STANOZOLOL; UNCLASSIFIED DRUG; ANABOLIC AGENT;

ACUTE KIDNEY FAILURE; ADULT; ADVERSE OUTCOME; ARTICLE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG USE; FOLLOW UP; HOSPITALIZATION; HUMAN; JAUNDICE; LIVER CELL DAMAGE; LIVER TOXICITY; MALE; MUSCLE MASS; PHENOTYPE; RISK FACTOR; ACUTE KIDNEY INJURY; AGED; BLOOD; CHOLESTASIS; COMPLICATION; DRUG-INDUCED LIVER INJURY; MIDDLE AGED; PATHOPHYSIOLOGY; YOUNG ADULT;

ACUTE KIDNEY INJURY; ADULT; AGED; ANABOLIC AGENTS; ANDROGENS; BILIRUBIN; CHOLESTASIS; CREATININE; DRUG-INDUCED LIVER INJURY; HUMANS; JAUNDICE; MALE; MIDDLE AGED; PHENOTYPE; RISK FACTORS; YOUNG ADULT;

EID: 84915746578     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13023     Document Type: Article

References (29)

1. Smith DA, Perry PJ. The efficacy of ergogenic agents in athletic competition. Part I: androgenic-anabolic steroids. Ann Pharmacother 1992; 26: 520-8.
2. Evans NA. Current concepts in anabolic-androgenic steroids. Am J Sports Med 2004; 32: 534-42.
3. Kanayama G, Hudson JI, Pope HG Jr. Illicit anabolic-androgenic steroid use. Horm Behav 2010; 58: 111-21.
4. FDA warning on body building products marketed a containing steroids or steroid-like substances. Available at: http://www.fda.gov/forconsumers/consumerupdates/ucm173739.htm (accessed March 13, 2014).
5. Far HR, Agren G, Thiblin I. Cardiac hypertrophy in deceased users of anabolic androgenic steroids: an investigation of autopsy findings. Cardiovasc Pathol 2012; 21: 312-6.
6. Lindqvist AS, Moberg T, Eriksson BO, et al. A retrospective 30-year follow-up study of former Swedish-elite male athletes in power sports with a past anabolic androgenic steroids use: a focus on mental health. Br J Sports Med 2013; 47: 965-9.
7. Sánchez-Osario M, Duarte-Rojo A, Martínz-Bení tez B, et al. Anabolicandrogenic steroids and liver injury. Liver Int 2008; 28: 278-82.
8. Stimac D, Milic S, Dintinjana RD, et al. Adrogenic/anabolic steroid-induced toxic hepatitis. J Clin Gastroenterol 2002; 35: 350-2.
9. Socas L, Zumbado M, Pérez-Luzardo O, et al. Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature. Br J Sports Med 2005; 39: e27.
10. Hardt A, Stippel D, Odenthal M, et al. Development of hepatocellular carcinoma associated with anabolic androgenic steroid abuse in a young bodybuilder: a case report. Case Rep Pathol 2012; 2012: 195607.
11. Cabasso A. Peliosis hepatitis in a young bodybuilder. Med Sci Sports Exerc 1994; 26: 2-4.
12. Krishnan PV, Feng ZZ, Gordon SC. Prolonged intrahepatic cholestasis and renal failure secondary to anabolic androgenic steroid-enriched dietary supplements. J Clin Gastroenterol 2009; 43: 672-5.
13. Kafrouni MI, Anders RA, Verma S. Hepatotoxicity associated with dietary supplements containing anabolic steroids. Clin Gastroenterol Hepatol 2007; 5: 809-12.
14. Shah NL, Zacharias I, Khettry U, et al. Methasteron-associated cholestatic liver injury: clinicopathologic findings in 5 cases. Clin Gastroenterol Hepatol 2008; 6: 255-8.
15. Andrade RJ, Lucena MI, Fernández MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512-21.
16. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990; 11: 272-6.
17. Aithal GP, Watkins PB, Andrade RJ, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011; 89: 806-15.
18. ATC/DDD Index 2014. Available at: http://www.whocc.no/atc-ddd-index/ (accessed January 28, 2014).
19. Sagoe D, Molde H, Andreassen CS, et al. The global epidemiology of anabolicandrogenic steroid use: a meta-analysis and meta-regression analysis. Ann Epidemiol 2014; 24: 383-98.
20. Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol 2008; 154: 502-21.
21. Morgan RE, Trauner M, van Staden CJ, et al. Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci 2010; 118: 485-500.
22. Erlinger S, Arias IM, Dhumeaux D. Inherited disorders of bilirubin transport and conjugation: new insights into molecular mechanisms and consequences. Gastroenterology 2014; 146: 1625-38.
23. Rafat C, Burbach M, Brocheriou I, et al. Bilirubin-associated acute tubular necrosis in a kidney transplant recipient. Am J Kidney Dis 2013; 61: 782-5.
24. Qian Q, Nath KA, Wu Y, et al. Hemolysis and acute kidney failure. Am J Kidney Dis 2010; 56: 780-4.
25. Lucena MI, Andrade RJ, Cabello MR, et al. Aminoglycoside-associated nephrotoxicity in extrahepatic obstructive jaundice. J Hepatol 1995; 22: 189-96.
26. Sellinger M, Haag K, Burckhardt G, et al. Sulfated bile acids inhibit Na (+)-H+ antiport in human kidney brush-border membrane vesicles. Am J Physiol 1990; 258: F986-91.
27. Robles-Diaz M, Lucena MI, Kaplowitz N, et al. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology 2014; 147: 109-18.
28. Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005; 42: 481-9.
29. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Available at: http://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/medIlegales/2013/docs/ICM-MI-09-2013-episdrol-epistane.pdf (accessed March 13, 2014).